Oct 16 (Reuters) -
Exelixis Inc. (EXEL) said on
Monday its drug to treat patients with a type of liver cancer met the main goal
in a late stage study, sending its shares up 19 percent in premarket trading.
The drug, cabozantinib, showed statistically significant
improvement in overall survival in advanced hepatocellular carcinoma patients
who had been previously treated with Bayer AG and Amgen's sorafenib, compared
with a placebo.
Exelixis plans to file for an expanded label for the drug with
the U.S. Food and Drug Administration in the first quarter of 2018.
http://www.foxbusiness.com/markets/2017/10/16/exelixis-liver-cancer-drug-meets-late-stage-goal-shares-jump.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Fhealthcare+%28Internal+-+Health+Care+-+Text%29&ito=792&itq=04ccf8ed-59a8-4a69-897b-a4328be50aaa&itx%5Bidio%5D=8812325
No comments:
Post a Comment